HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lymphangiosarcoma

A malignant tumor originating from the endothelial cells of lymphatic vessels. Most lymphangiosarcomas arise in an arm secondary to radical mastectomy but they sometimes complicate idiopathic lymphedema. The lymphedema has usually been present for 6 to 10 years before malignant changes develop. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1866)
Also Known As:
Lymphangioendotheliomas, Malignant; Lymphangiosarcomas; Malignant Lymphangioendothelioma; Malignant Lymphangioendotheliomas; Lymphangioendothelioma, Malignant
Networked: 90 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Stewart Treves syndrome
2. Breast Neoplasms (Breast Cancer)
3. Neoplasms (Cancer)
4. Lymphedema (Milroy Disease)
5. Neoplasm Metastasis (Metastasis)

Experts

1. Guan, Jun-Lin: 2 articles (01/2020 - 12/2015)
2. Sun, Shaogang: 2 articles (01/2020 - 12/2015)
3. Carvajal, Jose L: 1 article (07/2022)
4. Case, J Brad: 1 article (07/2022)
5. Fox-Alvarez, William A: 1 article (07/2022)
6. Regier, Penny J: 1 article (07/2022)
7. Toskich, Beau B: 1 article (07/2022)
8. Verpaalen, Valentine: 1 article (07/2022)
9. Vilaplana Grosso, Federico R: 1 article (07/2022)
10. Baxa, Jan: 1 article (11/2020)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Lymphangiosarcoma:
1. Mechanistic Target of Rapamycin Complex 1IBA
2. OsteopontinIBA
3. Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
4. Melphalan (Alkeran)FDA LinkGeneric
5. Factor VIII (Coagulation Factor VIII)IBA
6. Cytostatic AgentsIBA
7. Desmoplakins (Desmoplakin)IBA
8. Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA
9. AnthracyclinesIBA
10. von Willebrand FactorIBA

Therapies and Procedures

1. Radiotherapy
2. Radical Mastectomy
3. Drug Therapy (Chemotherapy)
4. Mastectomy (Mammectomy)
5. Therapeutics